Phenyl-tert-butylnitrone induces tumor regression and decreases angiogenesis in a C6 rat glioma model

Free Radical Biology and Medicine

Volumn 44, Issue 1, 2008, Pages 63-72

  Doblas, Sabrina ^a,b   Saunders, Debbie ^b   Kshirsagar, Preeti ^c   Pye, Quentin ^b   Oblander, Jenny ^b   Gordon, Brian ^b   Kosanke, Stanley ^d   Floyd, Robert A ^b,d   Towner, Rheal A ^b,d  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; C6 cells; Free radicals; Magnetic resonance angiography; Magnetic resonance imaging; Phenyl tert butyl nitrone; Rat glioma

Indexed keywords

N TERT BUTYL ALPHA PHENYLNITRONE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; GLIOMA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RAT; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; GLIOMA; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED F344; SOFTWARE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

RATTUS;

EID: 36249029226     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.09.006     Document Type: Article

References (42)

1. Central Brain Tumor Registry of the United States. Statistical report: primary brain tumors in the United States, 1998-2002. Chicago: CBTRUS; 2005.
2. Zhang X., Wu J., Gao D., Fei Z., Qu Y., and Jing J. Development of a rat C6 brain tumor model. Chin. Med. J. (Engl.) 115 (2002) 455-457
3. Grobben B., De Deyn P.P., and Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 310 (2002) 257-270
4. Sibenaller Z.A., Etame A.B., Ali M.M., Barua M., Braun T.A., Casavant T.L., and Ryken T.C. Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg. Focus 19 (2005) E1
5. Goldbrunner R.H., Wagner S., Roosen K., and Tonn J.C. Models for assessment of angiogenesis in gliomas. J. Neurooncol. 50 (2000) 53-62
6. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
7. Endoh H., Kato N., Fujii S., Suzuki Y., Sato S., Kayama T., Kotake Y., and Yoshimura T. Spin trapping agent, phenyl N-tert-butylnitrone, reduces nitric oxide production in the rat brain during experimental meningitis. Free Radic. Res. 35 (2001) 583-591
8. Miyajima T., and Kotake Y. Spin trapping agent, phenyl N-tert-butyl nitrone, inhibits induction of nitric oxide synthase in endotoxin-induced shock in mice. Biochem. Biophys. Res. Commun. 215 (1995) 114-121
9. Sang H., Wallis G.L., Stewart C.A., and Kotake Y. Expression of cytokines and activation of transcription factors in lipopolysaccharide-administered rats and their inhibition by phenyl N-tert-butylnitrone (PBN). Arch. Biochem. Biophys. 363 (1999) 341-348
10. Nakae D., Kotake Y., Kishida H., Hensley K.L., Denda A., Kobayashi Y., Kitayama W., Tsujiuchi T., Sang H., Stewart C.A., Tabatabaie T., Floyd R.A., and Konishi Y. Inhibition by phenyl N-tert-butyl nitrone of early phase carcinogenesis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Cancer Res. 58 (1998) 4548-4551
11. Hensley K., Abdel-Moaty H., Hunter J., Mhatre M., Mou S., Nguyen K., Potapova T., Pye Q.N., Qi M., Rice H., Stewart C., Stroukoff K., and West M. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J. Neuroinflammation 3 (2006) 2
12. Kobayashi N., Allen N., Clendenon N.R., and Ko L.W. An improved rat brain-tumor model. J. Neurosurg. 53 (1980) 808-815
13. In: Janzen E.G., Haire D.L., and Tanner D.D. (Eds). Two decades of spin trapping (1990), JAI Press, Greenwich
14. Rygaard K., and Spang-Thomsen M. Quantitation and Gompertzian analysis of tumor growth. Breast Cancer Res. Treat. 46 (1997) 303-312
15. Demicheli R., Foroni R., Giuliani F., and Savi G. Analysis of free growth and post-treatment regrowth of C3H mammary carcinoma in individual mice. Cell Tissue Kinet. 19 (1986) 471-476
16. Steel G.G. Growth kinetics of tumors (1977), Clarendon Press, Oxford
17. Goh V., Padhani A.R., and Rasheed S. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol. 8 (2007) 245-255
18. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324 (1991) 1-8
19. Acker T., and Plate K.H. Role of hypoxia in tumor angiogenesis-molecular and cellular angiogenic crosstalk. Cell Tissue Res. 314 (2003) 145-155
20. Choyke P.L., Dwyer A.J., and Knopp M.V. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 17 (2003) 509-520
21. Provenzale J.M., Wang G.R., Brenner T., Petrella J.R., and Sorensen A.G. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. Am. J. Roentgenol. 178 (2002) 711-716
22. *-weighted MR imaging. Radiology 211 (1999) 791-798
23. Moffat B.A., Chen M., Kariaapper M.S., Hamstra D.A., Hall D.E., Stojanovska J., Johnson T.D., Blaivas M., Kumar M., Chenevert T.L., Rehemtulla A., and Ross B.D. Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin. Cancer Res. 12 (2006) 1525-1532
24. Gossmann A., Helbich T.H., Kuriyama N., Ostrowitzki S., Roberts T.P., Shames D.M., van Bruggen N., Wendland M.F., Israel M.A., and Brasch R.C. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J. Magn. Reson. Imaging 15 (2002) 233-240
25. Brubaker L.M., Bullitt E., Yin C., Van Dyke T., and Lin W. Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice. Cancer Res. 65 (2005) 8218-8223
26. Vergely C., Renard C., Moreau D., Perrin-Sarrado C., Roubaud V., Tuccio B., and Rochette L. Effect of two new PBN-derived phosphorylated nitrones against postischaemic ventricular dysrhythmias. Fundam. Clin. Pharmacol. 17 (2003) 433-442
27. Hong W.K., and Sporn M.B. Recent advances in chemoprevention of cancer. Science 278 (1997) 1073-1077
28. Mann J.R., Backlund M.G., and Du Bois R.N. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol. 2 (2005) 202-210
29. Schreck R., Meier B., Mannel D.N., Droge W., and Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175 (1992) 1181-1194
30. Schmedtje Jr. J.F., Ji Y.S., Liu W.L., Du Bois R.N., and Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272 (1997) 601-608
31. Ambs S., Merriam W.G., Ogunfusika M.O., Bennett W.P., Ishibe N., Hussain S.P., Tzeng E.E., Geller D.A., Billiar T.R., and Harris C.C. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med. 4 (1998) 1371-1376
32. Andrade S.P., Hart I.R., and Piper P.J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br. J. Pharmacol. 107 (1992) 1092-1095
33. Bredt D.S., and Snyder S.H. Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem. 63 (1994) 175-195
34. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
35. Cobbs C.S., Brenman J.E., Aldape K.D., Bredt D.S., and Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55 (1995) 727-730
36. Lala P.K., and Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev. 17 (1998) 91-106
37. Chin K., Kurashima Y., Ogura T., Tajiri H., Yoshida S., and Esumi H. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 15 (1997) 437-442
38. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., and Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99 (1997) 2625-2634
39. Uhlmann S., Friedrichs U., Eichler W., Hoffmann S., and Wiedemann P. Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells. Microvasc. Res. 62 (2001) 179-189
40. Wu H.M., Huang Q., Yuan Y., and Granger H.J. VEGF induces NO-dependent hyperpermeability in coronary venules. Am. J. Physiol. 271 (1996) H2735-H2739
41. Xie Q.W., Whisnant R., and Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med. 177 (1993) 1779-1784
42. Pogrebniak H.W., Merino M.J., Hahn S.M., Mitchell J.B., and Pass H.I. Spin trap salvage from endotoxemia: the role of cytokine down-regulation. Surgery 112 (1992) 130-139